Afshin Taheriazam

Afshin Taheriazam


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2025 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
APAshkan Pouyan
Ashkan Pouyan
MGMasoud Ghorbanlo
Masoud Ghorbanlo
MEMasoud Eslami
Masoud Eslami
MJMajid Jahanshahi
Majid Jahanshahi
EZEhsan Ziaei
Ehsan Ziaei
MHMehrdad Hashemi
Mehrdad Hashemi
Glioblastoma multiforme (GBM) is the most prevalent and aggressive primary brain tumor in adults, characterized by a poor prognosis and significant resistance to existing treatments. Despite progress in therapeutic strategies, the median overall survival remains approximately 15 months. A hallmark of GBM is its intricate molecular profile, driven by disruptions in multiple signaling pathways, including PI3K/AKT/mTOR, Wnt, NF-κB, and TGF-β, critical to tumor growth, invasion, and treatment resistance. This review examines the epidemiology, molecular mechanisms, and therapeutic prospects of targeting these pathways in GBM, highlighting recent insights into pathway interactions and discovering new therapeutic targets to improve patient outcomes.

15 June 2022 in Pharmacological Research
Verified
Journal Article
Closed access
MSMehrdokht Sadrkhanloo
Mehrdokht Sadrkhanloo
MEMaliheh Entezari
Maliheh Entezari
SOSima Orouei
Sima Orouei
MGMarzieh Ghollasi
Marzieh Ghollasi
NFNikoo Fathi
Nikoo Fathi
SSSaeed Samarghandian
Saeed Samarghandian

28 August 2022 in Pharmacological Research
Verified
Journal Article
Closed access
MHMehrdad Hashemi
Mehrdad Hashemi
MMMarzieh Sadat Moosavi
Marzieh Sadat Moosavi
HAHedyeh Maghareh Abed
Hedyeh Maghareh Abed
MDMaryam Dehghani
Maryam Dehghani
MAMasoumeh Aalipour
Masoumeh Aalipour
SSSaeed Samarghandian
Saeed Samarghandian

15 November 2022 in Pharmacological Research
Verified
Journal Article
Open access
MPMahshid Deldar Abad Paskeh
Mahshid Deldar Abad Paskeh
FGFatemeh Ghadyani
Fatemeh Ghadyani
MHMehrdad Hashemi
Mehrdad Hashemi
AAAlireza Abbaspour
Alireza Abbaspour
AZAmirhossein Zabolian
Amirhossein Zabolian
Gautam SethiGautam Sethi
Gautam Sethi
Cancer progression results from activation of various signaling networks. Among these, PI3K/Akt signaling contributes to proliferation, invasion, and inhibition of apoptosis. Hepatocellular carcinoma (HCC) is a primary liver cancer with high incidence rate, especially in regions with high prevalence of viral hepatitis infection. Autoimmune disorders, diabetes mellitus, obesity, alcohol consumption, and inflammation can also lead to initiation and development of HCC. The treatment of HCC depends on the identification of oncogenic factors that lead tumor cells to develop resistance to therapy. The present review article focuses on the role of PI3K/Akt signaling in HCC progression. Activation of PI3K/Akt signaling promotes glucose uptake, favors glycolysis and increases tumor cell proliferation. It inhibits both apoptosis and autophagy while promoting HCC cell survival. PI3K/Akt stimulates epithelial-to-mesenchymal transition (EMT) and increases matrix-metalloproteinase (MMP) expression during HCC metastasis. In addition to increasing colony formation capacity and facilitating the spread of tumor cells, PI3K/Akt signaling stimulates angiogenesis. Therefore, silencing PI3K/Akt signaling prevents aggressive HCC cell behavior. Activation of PI3K/Akt signaling can confer drug resistance, particularly to sorafenib, and decreases the radio-sensitivity of HCC cells. Anti-cancer agents, like phytochemicals and small molecules can suppress PI3K/Akt signaling by limiting HCC progression. Being upregulated in tumor tissues and clinical samples, PI3K/Akt can also be used as a biomarker to predict patients' response to therapy.

3 October 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MHMehrdad Hashemi
Mehrdad Hashemi
HAHamid Zaferani Arani
Hamid Zaferani Arani
SOSima Orouei
Sima Orouei
SFShayan Fallah
Shayan Fallah
AGAmin Ghorbani
Amin Ghorbani
KHKiavash Hushmandi
Kiavash Hushmandi
One of the malignant tumors in women that has involved both developed and developing countries is breast cancer. Similar to other types of tumors, breast cancer cells demonstrate high metastatic nature. Besides, breast tumor cells have ability of developing drug resistance. EMT is the related mechanism to cancer metastasis and focus of current manuscript is highlighting function of EMT in breast tumor malignancy and drug resistance. Breast tumor cells increase their migration by EMT induction During EMT, N-cadherin and vimentin levels increase, and E-cadherin levels decrease to mediate EMT-induced breast tumor invasion. Different kinds of anti-cancer agents such as tamoxifen, cisplatin and paclitaxel that EMT induction mediates chemoresistance feature of breast tumor cells. Furthermore, EMT induction correlates with radio-resistance in breast tumor. Clinical aspect is reversing EMT in preventing chemotherapy or radiotherapy failure in breast cancer patients and improving their survival time. The anti-tumor agents that suppress EMT can be used for decreasing breast cancer invasion and increasing chemosensitivity of tumor cells. Furthermore, lncRNAs, miRNAs and other factors can modulate EMT in breast tumor progression that are discussed here.

21 November 2022 in Pharmacological Research
Verified
Journal Article
Closed access
MHMehrdad Hashemi
Mehrdad Hashemi
MMMotahare Sadat Ayat Mirdamadi
Motahare Sadat Ayat Mirdamadi
YTYasmin Talebi
Yasmin Talebi
NKNasrin Khaniabad
Nasrin Khaniabad
GBGooya Banaei
Gooya Banaei
Prof. Dr. Haroon KhanProf. Dr. Haroon Khan
Prof. Dr. Haroon Khan